Point72 Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Point72 Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Sell	106,535 -228,465	-68%	-$3.21M	﹤0.01%	2511
2025 Q4	$4.05M	Sell	335,000 -2,455,066	-88%	-$33.3M	﹤0.01%	1986
2025 Q3	$37.9M	Sell	2,790,066 -1,746,200	-38%	-$16.4M	0.06%	328
2025 Q2	$29.1M	Buy	4,536,266 +3,619,300	+395%	+$17.6M	0.06%	378
2025 Q1	$3.25M	Buy	+916,966	New	+$3.26M	0.01%	1094
2024 Q4	–	Sell	-200	Closed	-$648	–	2058
2024 Q3	$648	Buy	+200	New	+$450	﹤0.01%	1931
2024 Q2	–	Sell	-170,000	Closed	-$483K	–	1829
2024 Q1	$483K	Sell	170,000 -2,581,305	-94%	-$33.8M	﹤0.01%	1659
2023 Q4	$40.5M	Buy	2,751,305 +2,751,259	+5,980,998%	+$42.2M	0.1%	260
2023 Q3	$842	Sell	46 -7,061	-99%	-$149K	﹤0.01%	2370
2023 Q2	$153K	Sell	7,107 -317,693	-98%	-$8.58M	﹤0.01%	1482
2023 Q1	$9.53M	Sell	324,800 -1,803,160	-85%	-$62.6M	0.03%	561
2022 Q4	$78.6M	Buy	2,127,960 +1,660,999	+356%	+$58.9M	0.27%	90
2022 Q3	$13.1M	Buy	466,961 +154,500	+49%	+$3.85M	0.05%	433
2022 Q2	$6.02M	Buy	+312,461	New	+$3.71M	0.03%	654

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management's AMLX Position: Q1 2026 in Review

Point72 Asset Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 68% in Q1 2026, selling an estimated $3.21M and leaving 106,535 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2511.

Point72 Asset Management first reported a position in AMLX in Q2 2022 and has held it in 14 quarters since. The position peaked at $78.6M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Point72 Asset Management held 106,535 shares of Amylyx Pharmaceuticals worth $1.48M as of Q1 2026.
Point72 Asset Management sold 228,465 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.21M.
Amylyx Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2511 holding.
Point72 Asset Management first reported a position in Amylyx Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
Point72 Asset Management's Amylyx Pharmaceuticals position peaked at $78.6M in Q4 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.